Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effexor XR TQT Study
NCT02637193Phase 1Completed
- Sponsor
- Viatris
- Start
- Dec 2015
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of venlafaxine in major depressive disorder (MDD) and generalized anxiety disorder (GAD) (3 arms), sponsored by Viatris. Primary endpoint: Postdose QTcF (Fridericia's correction) intervals. Started Dec 2015; status: completed.
02
Drugs
venlafaxine
03
Conditions
major depressive disorder (MDD)generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT02637193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02637193.